Publication Date
2-5-2024
Journal
Bio-protocol Journal
DOI
10.21769/BioProtoc.4931
PMID
38379831
PMCID
PMC10875358
PubMedCentral® Posted Date
2-5-2024
PubMedCentral® Full Text Version
Post-Print
Published Open-Access
yes
Keywords
AAV, Suspension cells, Serum-free media, Transfection reagent, Iodixanol density gradient
Abstract
Recombinant adeno-associated viruses (rAAVs) are valuable viral vectors for in vivo gene transfer, also having significant ex vivo therapeutic potential. Continued efforts have focused on various gene therapy applications, capsid engineering, and scalable manufacturing processes. Adherent cells are commonly used for virus production in most basic science laboratories because of their efficiency and cost. Although suspension cells are easier to handle and scale up compared to adherent cells, their use in virus production is hampered by poor transfection efficiency. In this protocol, we developed a simple scalable AAV production protocol using serum-free-media-adapted HEK293T suspension cells and VirusGEN transfection reagent. The established protocol allows AAV production from transfection to quality analysis of purified AAV within two weeks. Typical vector yields for the described suspension system followed by iodixanol purification range from a total of 1 × 10
Included in
Endocrine System Diseases Commons, Endocrinology, Diabetes, and Metabolism Commons, Medical Sciences Commons